Some studies have suggested that a significant fraction of nonHodgkin's lymphomas (NHL) do not express pRB protein, possibly due to deletions of RB1. We examined RB1/centromere 17 copy number by fluorescent in situ hybridisation, and pRB expression/phosphorylation by immunohistochemistry (IHC) and immunoblotting (IB) in 66 cases of B cell NHL. Thirteen cases had lost one RB1 copy relative to centromere 17 copy number and total DNA content. Case 458/88 had no RB1 copies. pRB levels were heterogeneous as assessed by IB (0.04-1.12 relative units), but all tumours, except for case 458/88, expressed pRB localised to the nucleus in Ͼ75% of the tumour cells by IHC. The fraction of phosphorylated pRB was correlated with pRB expression (r 2 = 0.56, P Ͻ 0.001). The 14 cases with loss of RB1 had lower pRB expression (median 0.25) than those without (median 0.48, P Ͻ 0.001), but a correlation with S phase fraction (r 2 = 0.43, P Ͻ 0.001; previously published data for tumour-specific S phase and apoptotic fractions) indicated that the variation in pRB expression was due to differences in proliferative activity. Furthermore, the regression lines for pRB expression vs S phase fraction were not different for the cases with or without loss of one RB1 copy (P = 0.5). Cases 154/88 (one RB1 copy) and 258/88 (two RB1 copies), in addition to case 458/88, had low expression of (hypophosphorylated) pRB (0.04, 0.08 and 0.04), despite their high S phase fractions (21%, 17% and 21%). There was no association between pRB expression/RB1 copy number and apoptotic fraction. Neither pRB expression nor loss of RB1 had prognostic value, but cases 154/88, 258/88, and 458/88 had short survival times (5, 3 and 46 months, respectively) compared to the others (median survival: 44 months, P = 0.03). It is suggested that pRB expression and function are normal in 63 of 66 NHL cases, including 12 of 13 lymphomas with loss of one RB1 allele.
Introduction
Non-Hodgkin's lymphoma (NHL) is a heterogeneous group of lymphoid tumours, however, most of them are of B cell origin. 1 Most subgroups of B cell lymphomas are characterised by specific genetic translocations. The translocations typically involve juxtaposed immunoglobulin genes and protooncogenes, such as t(14;18)/BCL2 in follicle centre lymphomas (FCL), t(11;14)/CCND1 in mantle cell lymphomas (MCL), t(3;14)/BCL6 in B cell diffuse large cell lymphomas (DLBCL), and t(8;14)/MYC in Burkitt's lymphomas (BL).
2 Secondary genetic aberrations could possibly explain variations in clinical phenotypes and patient survival. 3, 4 Loss of 13q14 is a frequent finding in lymphoid malignancies. This aberration has been detected in all subclasses of lymphomas. [5] [6] [7] A target for the deletion has not yet been established. Originally, it was suggested that RB1, localised to this region, was the candidate tumour suppressor gene involved. Liu et al 8 could not find mutations in the remaining RB1 allele in CLL cases with loss of one allele, and they suggested the relevant gene to be localised telomeric of RB1. Later studies in CLL and MCL have confirmed more frequent deletions telomeric of RB1 locus in lymphoid tumours, and have suggested a candidate tumour suppressor gene to be in the vicinity of the marker D13S319. 7, 9 The hypophosphorylated and active form of pRB binds to and regulates many cellular proteins, including the E2F family of transcription factors. Hypophosphorylated pRB is found firmly bound in the nucleus in resting cells and during the early G 1 phase of the cell cycle of proliferating cells. 10 Following stimulation of quiescent cells, pRB expression increases, [10] [11] [12] [13] cyclin-dependent kinases are activated, and subsequent phosphorylation of pRB leads to release of E2Fs. The released E2F transcription factors up-regulate important genes for S phase entry and cell cycle progression.
14 Apart from negative cell cycle regulation, pRB has also been shown to inhibit apoptosis. It is possible that protection from apoptosis by pRB proceeds through binding and inactivation of E2F-1. 15, 16 Abnormalities affecting the retinoblastoma (RB1) pathway, ie lack of pRB expression or expression of a mutant pRB, and inappropriate phosphorylation of pRB, leading to deregulated G 1 -S phase transition occur frequently in malignant disorders. [17] [18] [19] In some types of solid tumours, pRB is often either not expressed due to deletions of RB1, or a mutant protein is expressed. 20, 21 The results of studies of pRB expression in NHL are diverging and inconclusive. The discrepancies may be explained by different grading and staining methods. Martinez et al 22 and Weide et al 23 reported a reduction or loss of pRB expression by immunohistochemistry (IHC) in a large proportion of lymphomas. Kornblau et al 24 described reduced or no pRB expression in more than 30% of chronic lymphocytic leukemia (CLL) samples. Møller et al 25 found that four of 34 (12%) DLBCL expressed abnormally low levels of pRB (Ͻ10% stained nuclei), as assessed by IHC. In another recent IHC study of pRB expression in NHL, no staining was found in 80% of SLL, 28% of FCL, 32% of MCL and 6% of DLBCL. 26 However, others have reported no loss of pRB, assessed by IHC/IB in MCL and FCL/DLBCL samples. 27, 28 Geradts et al 29 published one tumour out of 101 NHL samples lacking pRB. Point mutations and small deletions leading to expression of an aberrant pRB protein are only infrequently found in NHL. 30, 31 Mutant pRB is not phosphorylated and does not bind nuclear structures or E2F, [32] [33] [34] [35] suggesting that most mutant pRBs are non-functional. Other oncogenic alterations in regulators upstream (p16
INK4A
, cyclin D1), as well as downstream (E2F-1) of pRB phosphorylation, 25, 36 may account for the majority of NHL cases with aberrations in the RB1 pathway.
Here we report RB1 copy number, and pRB expression lev-els and phosphorylation status in 66 cases of B-cell NHL. pRB expression and phosphorylation were normal, ie proliferation dependent, in 63 cases, even if 12 of these 63 cases had lost one RB1 allele. Our study suggests that normal levels of a functional pRB protein are expressed in the majority of NHL cases.
Materials and methods

Patients
Cell suspensions prepared from 66 histologically and immunologically verified B cell NHL were analysed. 
Fluorescent in situ hybridisation (FISH)
RB1 copy number was determined by interphase FISH. Dualcolour FISH (cohybridisation) with a spectrum orange labelled locus-specific RB1 probe and a spectrum green labelled centromere 17 probe from Vysis (Downers Grove, IL, USA) were applied to all tumours. RB1 copy number data for 45 of the lymphomas presented here have been published previously with a description of the methods used. 37 The present study includes RB1/centromere 17 results for 21 additional NHL cases.
pRB protein analysis by immunohistochemistry (IHC)
Five-m tissue sections from formalin-fixed, paraffin-embedded blocks were stained for pRB with a biotin-streptavidin amplified (B-SA) system using the Optimax Automated Cell Staining System Plus (BioGenex, San Ramon, CA, USA), and the anti-pRB antiserum C-15 (Santa Cruz Biotech, Santa Cruz, CA, USA). After mounting on to saline-coated slides, the sections were dried in a 56°C incubator for 1 h and overnight at 37°C. Deparaffinised and rehydrated sections were incubated with 0.3% hydrogen peroxide (H 2 O 2 ) in methanol for 30 min to block endogenous peroxidase activity. Sections were microwaved twice for 5 min each in citrate-buffer solution prior to incubation with the primary antibody. The primary antibody was detected with secondary reagents as suggested by the supplier (BioGenex). After visualisation of the immune reaction with DAB, and counterstaining with haematoxylin, the sections were dehydrated and cover-slipped. Semi-quantitative evaluation of the number of immunoreactive cells was done as reported previously. 40 All IHC experiments included positive biological controls (lymphoma and normal endometrial epithelium). Negative controls included substitution of the primary antibody with a non-reacting antibody of the same class. pRB peptide (Santa Cruz) blocking of the pRB antibody (absorption) was also done according to the manufacturer's pRB expression and RB1 deletions in non-Hodgkin's lymphomas E Galteland et al 1551 recommendation. The immunoreactivity was limited to the cell nuclei.
pRB protein analysis by immunoblotting (IB)
Thawed cells were washed in phosphate-buffered saline (PBS) buffer containing 0.1 mM phenylmethylsulfonylfluoride (PMSF) and counted. The cell pellet was boiled for 5 min in sodium dodecyl sulphate (SDS) sample buffer containing the protease inhibitors leupeptin, aprotinin, benzamidine and PMSF. The proteins were first separated by electrophoresis in 10% SDS-polyacrylamide gels. Lysates of 500 000 cells were loaded per lane. The proteins were then blotted over to Immobilon polyvinyldifluoride (PVDF) transfer membranes (Millipore, Bedford, MA, USA), and stained with the monoclonal anti-pRB antibody PMG3-245 (0.6 g/ml; Pharmingen, San Diego, CA, USA) using a biotin-streptavidin alkaline phosphatase staining procedure to detect the primary antibodies (Amersham, Buckinghamshire, UK). The secondary detection reagents reacted non-specifically with a protein migrating at approximately 125 kDa. 10 As a control for gel loading, cell concentration, and protein degradation, the amount of p83 was determined on the same blots using the monoclonal antip83 antibody 34C1. p83 is a protein distributed diffusely and abundantly throughout the nucleoplasm of all human cells tested. The amount of p83 per cell does not appear to vary with growth rate or tissue origin. 38, [41] [42] [43] The amounts of the different proteins were evaluated by densitometry using the ImageQuant densitometry software (Molecular Dynamics, Sunnyvale, CA, USA) to analyse stored digital gel images generated with a Hewlett Packard Scan Jet 6200C photo scanner (HP, Palo Alto, CA, USA). Intensities were integrated from 105-120 kDa to avoid contribution from the non-specific band at approximately 125 kDa. Levels of pRB are reported relative to p83 expression. The cell line Daudi, which expresses high amounts of pRB, was employed as a control in all experiments to ensure interassay reproducibility. The pRB/p83 ratios for the tumours in a particular experiment were normalised to the corresponding ratio for Daudi to compensate for small changes in the relative sensitivity of the anti-pRB and anti-p83 antibodies between experiments. The fraction of phosphorylated pRB was determined as the integrated intensity to the high molecular weight side of the main peak of (hypophosphorylated) pRB at 110 kDa, relative to total levels of pRB. Employing these criteria, the fraction of phosphorylated pRB was 49% (s.d. = 7, n = 9) for Daudi, and 8% (s.d. = 2, n = 4) for non-proliferating peripheral blood lymphocytes.
Statistical analysis
Relevant statistical tests were performed using the SigmaStat (Jandel Scientific, Erkrath, Germany) and SPSS (SPSS, Chicago, IL, USA) software packages. T-tests or Mann-Whitney twotailed test were applied to check for significant differences between two data groups for a specific parameter. Correlations were assessed with linear regression analysis. Cancerspecific survival was determined from the time of the relevant biopsy. Death from any cancer or treatment complications defined an event. Other deaths were censored. The significance of differences in survival between two groups was calculated using the log-rank test. P values below 0.05 were considered to reflect statistical significance.
Leukemia
Results
RB1 copy number
The tumour cells in 11 of 66 tumour samples had one RB1 copy (Table 1) , all of these were near-diploid by flow cytometry and had two centromere 17 copies (ploidy data taken from Ref. 44) . Case 458/88 had no RB1 copies. Case 358/87 had three RB1 and four centromere 17 copies (DI = 1.94). Two clones were present in case 309/89 (only one peak found in DNA histograms by FCM; DI = 1.83), one with two RB1 and three centromere 17 copies, the other with three RB1 and four centromere 17 copies. The latter two cases were included in the group with RB1 loss. Fifty samples had tumour cell clones with the same RB1 and centromere 17 copy number. Fortysix of these cases had two RB1/centromere 17 copies and three cases had four RB1/centromere 17 copies. Two clones were present in case 258/88, one with two RB1/centromere 17 copies, and the other with four RB1/centromere 17 copies (Table 1) . Two tumours had RB1 gain with three RB1 and two centromere 17 copies. Among the four major subtypes of NHL, RB1 deletion was most frequently found in MCL and SLL (Table 1) . Cases 140/83, 315/92, 315/88 and 458/88 had loss of RB1, but no deletions on chromosome 13 were observed employing comparative genomic hybridisation (Table 1) .
pRB expression and phosphorylation
Immunohistochemistry (IHC) revealed that more than 75% of the tumour cells expressed pRB in the nucleus in all 66 tumours, except for case 458/88, in which less than 5% of the tumour cells were stained for pRB. pRB was detected in all samples by immunoblotting, including case 458/88 ( Figure 1 , Table 1 ). However, very low expression was observed in several cases, including cases 458/88 (0.04; negative by immunohistochemistry), 154/88 (0.04), and 258/88 (0.08; Figure 1, Table 1 ; cases 154/88 and 258/88 will be discussed later). The presence of pRB in normal cells will obviously contribute to the IB results, as exemplified by case 458/88 with 11% normal cells ( Table 1 , the fractions of tumour and normal cells, as measured by flow cytometry, were taken from Ref. 44) . The mean tumour cell fraction in all samples was 77% (s.d. = 12%), all cases had more than 50% tumour cells. With this high fraction of tumour cells, we employed the IB result as a measure of pRB expression. pRB levels were non-normally distributed, ranging from 0.04 to 1.12. The median pRB value for all NHL cases was 0.40 (25% percentiles 0.29, 0.67). The mean fraction of tumour cells was similar for the cases with and without RB1 deletion (79% and 76%, respectively, P = 0.33). Median pRB in tumours with normal or enhanced RB1 copy number (n = 52) was higher (0.48, 25% percentiles 0.32, 0.71) than in the tumours with deletion (n = 14) (0.25, 25% percentiles 0.11, 0.33) (P Ͻ 0.001).
In the cases with low pRB expression, most of the protein migrated as a single band with an apparent molecular weight of 110 kDa (Figure 1a ; examples provided by PBL and cases 140/90, 416/90, 159/90, 445/89, 458/88, 154/88, 258/88; Table 1 ). In contrast, a large fraction of pRB migrated as a broad band with apparent molecular weights from 110 kDa up to 120 kDa in the cases with high pRB expression ( Figure  1a ; examples provided by Daudi and cases 90/89, 438/89, 472/90, 577/90, 131/89; Table 1 ), compatible with phosphorylation of a large fraction of the pRB molecules. Accord-
Figure 1
Analysis of pRB expression and phosphorylation by immunoblotting. (a) pRB and p83 levels and molecular weights (pRB) were detected by IB in lymphoma samples, a lymphoma cell line (Daudi) and peripheral blood lymphocytes (PBL). Lysates of 500 000 cells were loaded in each lane. p83 was used as a control for protein degradation in the individual samples. (b) Blots such as the one(s) shown in (a) were scanned and the areas under the peaks were used as a measure of protein levels in lymphomas with normal or enhanced RB1 copy number (b), lymphomas with loss of one RB1 copy (ć), and case 458/88 with no RB1 alleles (̆). pRB levels are reported relative to the levels of p83. Lysates from the same batch of Daudi cells were used as a positive control in all experiments. To compensate for any differential sensitivity of the two antibodies in different experiments, the results from different blots were further normalised according to the pRB expression relative to p83 for Daudi. The fraction of phosphorylated pRB was determined as the integrated intensity to the high molecular weight side of the main peak of (hypophosphorylated) pRB at 110 kDa, relative to total levels of pRB. pRB expression and phosphorylation were strongly correlated (r 2 = 0.56, P Ͻ 0.001). The regression line and the 99% prediction interval are given. The fraction of phosphorylated pRB was 49% (s.d. = 7, n = 9) for Daudi, and 8% (s.d. = 2, n = 4) for non-proliferating peripheral blood lymphocytes.
ingly, there was a correlation between pRB expression and phosphorylation (r 2 = 0.56, P Ͻ 0.001; Figure 1b) .
pRB expression and proliferation/apoptosis
pRB expression was plotted against S phase fraction for each sample (Figure 2a ; data for S phase and apoptotic fractions were obtained from Ref. 39) . pRB expression and S phase fraction were significantly correlated (r 2 = 0.43, P Ͻ 0.001). Cases 154/88, 258/88 and 458/88 were obvious exceptions with low pRB assessed by IB (0.04, 0.08, 0.04), even though the S phase fraction was high (21%, 17%, 21%, respectively; Table 1 ). 458/88 had lost both RB1 alleles, and as expected, was negative for pRB by IHC. However, in the former two cases with one and two RB1 copies, respectively, more than 75% of the tumour cells were positive for pRB. Hence, pRB expression in the tumour cells in cases 154/88 and 258/88 was comparable to or lower than the expression in non-proliferating lympho-
Figure 2
Correlation of pRB expression with tumour-specific S phase fraction, but not with apoptotic fraction, in 66 NHL cases. pRB expression by IB was plotted vs tumour-specific S phase fraction (a) or apoptotic fraction (b) in lymphomas with normal or enhanced RB1 copy number (b), lymphomas with loss of one RB1 copy (ć), and case 458/88 with no RB1 alleles (̆). There was a significant correlation between pRB expression and S phase fraction for the cases with normal or enhanced RB1 copy number (r 2 = 0.54, P Ͻ 0.001; solid lines), as well as for the cases with loss of one RB1 allele (r 2 = 0.48, P = 0.01; dashed lines). However, the regression lines for the cases with normal/enhanced RB1 and loss of one RB1 copy were not different (P = 0.5). There was no correlation between pRB expression and tumour apoptotic fraction (r 2 = 0.01, P = 0.51), and no difference in apoptotic fraction between the NHL cases with normal/increased RB1 copy number and those with loss of one RB1 copy (P = 0.64). Regression lines and the 99% prediction intervals are given.
cytes. It was confirmed by IHC that the pRB expression in the tumour cells in the two latter cases was equal to or lower than the normal (non-proliferating) lymphocytes in the same sections. Cases 154/88, 258/88 and 458/88 also had low fractions of phosphorylated pRB (8%, 6% and 5%, respectively; Figure 1b , Table 1 ), as well as aberrations in the TP53/p53 pathway ( Table 1) . The correlation between pRB expression and S phase fraction (excluding cases 154/88, 258/88 and 458/88), could indicate that the lower pRB expression in the cases with loss of one RB1 allele was due to a lower degree of proliferation relative to the others. The relationship between pRB expression and S phase fraction was assessed separately for the cases with and without RB1 loss (Figure 2a) . A significant correlation was found in both cases, and, additionally, the regression lines for pRB expression vs S phase fraction pRB expression and RB1 deletions in non-Hodgkin's lymphomas E Galteland et al
1553
were not different for the NHL cases with normal/increased RB1 copy number and those with loss of one RB1 copy (P = 0.5).
pRB expression was not correlated with the fraction of apoptotic tumour cells (Figure 2b ; r 2 = 0.01, P = 0.51). There was no difference in tumour apoptotic fraction between the NHL cases with normal/increased RB1 copy number and those with loss of one RB1 copy (Figure 2b ; P = 0.64).
pRB expression and survival
We further assessed whether pRB expression or RB1 copy number had any impact on patient survival. Median survival was 53 months and 24 months in the groups with pRB expression below and above median, respectively, but the difference was not significant (log-rank test; P = 0.18). Median survival was 46 months and 33 months in the group with and without RB1 deletion, respectively (P = 0.81). Aberrations in the p53 pathway, which were found at approximately the same frequency among the cases with and without RB1 deletion (P = 0.49; Table 1 ), had high prognostic value (median survival for cases with/without aberrations in the p53 pathway: 7 months/70 months; P Ͻ 0.0001). The survival of the three cases with aberrant pRB expression in relation to the S phase fraction (cases 154/88, 258/88 and 458/88 with survival times of 5, 3 and 46 months, respectively) was significantly shorter than for the other cases (median survival: 44 months; P = 0.03). However, all three cases also had TP53/p53 aberrations ( Table 1) .
Discussion
Lymphoid malignancies, including NHL, frequently show loss of chromosome band 13q14 and RB1, which could lead to decreased or no expression of pRB, also in the cases with loss of only one allele. We report here the expression and phosphorylation of pRB in relation to RB1 copy number and tumour cell proliferation/apoptosis in 66 cases of B-cell NHL. pRB was expressed in all cases, but at different levels, except in one case with loss of both RB1 alleles. There was a strong correlation between pRB expression and the fraction of phosphorylated pRB, as well as between pRB expression and S phase fraction. The dependence between pRB expression and S phase fraction was similar in the cases with and without loss of one RB1 allele. Two cases, however, with one and two RB1 alleles, had low pRB expression and pRB phosphorylation levels in view of their high S phase fractions. Thus, the expression and phosphorylation status of pRB was normal and proliferation-dependent in 63 of 66 cases of B cell NHL, including 12 of 13 cases with loss of one RB1 allele.
The overall frequency of RB1 deletions in our material was 21%, with the highest incidence in MCL (46%) and SLL (23%). This is in very good agreement with the results of Cuneo et al, 45 who employed a FISH probe located between RB1 and the D13S25 for their deletion studies. Four tumours were found with loss of RB1, but with no loss on chromosome 13q by comparative genomic hybridisation, indicating that the deleted regions around RB1 were small in those cases ( Table  1) . Studies of the 13q14 deletions in lymphoid neoplasia have indicated that RB1 may not be the affected gene in B cell NHL, 7, 9 however, this situation may be different in other haematological neoplasms. 46, 47 If the RB1 gene was the main target in the cases with 13q14 Leukemia deletions, reduced or no pRB expression would be expected. While some studies have suggested that a considerable fraction of NHL cases do not express pRB, [22] [23] [24] [25] other studies, [27] [28] [29] and the present study, report that pRB is expressed in the large majority of malignant lymphomas (65 of 66 cases in our study). Consistent with previous studies, 26, 27 there was a large variation in expression (Ͼ20-fold). The cases with deletion of one RB1 allele had lower pRB expression and phosphorylation than the others, however, the cases with deletion also had lower S phase fractions. Since up-regulation of pRB levels is a feature of mitogen-stimulated normal lymphocytes, the reduced pRB expression in the NHL cases with loss of one RB1 allele may be the result of a low proliferation rate. This is further supported by a similar functional dependence between pRB expression and S phase fraction for the cases with and without loss of one RB1 allele (Figure 2a ). In contrast, no association was found between pRB expression/RB1 copy number and apoptotic fraction. The expression of some tumour suppressor genes, eg TP53, 38 seems to be dependent on gene dosage, but this is probably not the case for RB1 (this study; reviewed by Cook and McCaw 48 ). Based on the correlation between pRB expression and S phase fraction, three cases were identified with reduced pRB expression. Among these, case 458/88 had no RB1 alleles, and the tumour cells in this case were negative by IHC. Cases 154/88 and 258/88 with high S phase fractions, showed weak expression in the tumour cells, and the expressed pRB was not hyperphosphorylated. These latter two cases had one and two RB1 alleles, respectively. In view of the normal, proliferation-dependent expression in the other cases with one RB1 allele, it is not suggested that the reduced expression in case 154/88 is due to the presence of only one RB1 allele. Alternative mechanisms for down-regulation of pRB levels include reduced transcription of the RB1 gene, eg caused by promoter methylation, 49 reduced translation of the RB1 mRNA, as well as a reduced half-life of the mRNA and protein. It is also possible that the RB1 gene harbours point mutations in cases 154/88 and 258/88, although such mutations are rarely found in NHL. 30, 31 With regard to prognosis, Cuneo et al 45 found a significant association between 13q14 loss and shorter survival. This result was supported by Wada et al, 6 who found monoallelic loss of RB1 more frequently in aggressive NHL compared to indolent tumours. In our study, there was no significant association between survival and RB1 copy number or pRB expression. Three cases with aberrant pRB expression (in relation to their high S phase fractions), survived shorter than the others. These three cases also had p53 aberrations, which are associated with a poor prognosis in NHL. 4, 38, 50, 51 However, it has been suggested that concomitant inactivation of the RB1 and p53 pathways leads to additional growth advantage and aggressiveness in NHL. 52, 53 Aberrations in the RB1 pathway leading to loss of G 1 restriction point control are traditionally thought to be mutually exclusive, eg tumours with inactivating RB1 mutations in general show no elevation in cyclin D1 expression. 54, 55 Twelve of the 13 MCL cases in this study (excluding case 67/92), and SLL case 339/89 showed (over)expression of cyclin D1 caused by a t (11;14) translocation (all of the others were negative; unpublished results). Seven of the 13 cases with cyclin D1 expression had a low S phase fraction (Ͻ3%), indicating that cyclin D1 expression alone is not sufficient to cause a complete deregulation of the G 1 -S transition in NHL. Moreover, MCL cases with cyclin D1 overexpression caused by a t(11;14) translocation may show deletion of both CDKN2A Leukemia alleles (encoding for the CDK4/cyclin D1 inhibitor p16). 36 Deletions at 9p21, possibly indicative of CDKN2A homozygous loss, were almost exclusively associated with MCL. 44 BL-like case 458/88 also had loss of 9p21, 44 preliminary results of quantitative PCR experiments indicate that both copies of exon 3 of CDKN2A are lost. Neither case 458/88, nor any of the other 65 cases reported here, express p16 clonally, in contrast to the clonal p16 expression observed in HPVtransformed cervical cancer cell lines (unpublished results). Hence, case 154/88 had cyclin D1 expression, reduced pRB expression, and loss of at least one CDKN2A allele, while case 458/88 had no pRB expression and loss of both CDKN2A alleles. It is possible that there is cross talk between the 'RB1 pathway' and other pathways important for the control of entry into S phase, and that aberrations in more than one component of the RB1 pathway are required in many cases for a complete deregulation of proliferation.
